[The efficacy of lanikor in treating patients with chronic cor pulmonale].

Abstract

Cardiac glycoside lanicor produced in Yugoslavia ("Pliva") was administered to 43 patients with decompensated chronic cor pulmonale (DCCP). Blood concentrations of the drug given at a dose of 0.25 mg were evaluated over 24 h, in peak saturation, during therapy with maintenance doses. A daily loss of therapeutic activity of the drug was established. The total, mean and maintenance doses were determined. Tetrapolar rheography and right ventricular kinetocardiography found lanicor-related changes in the central and pulmonary hemodynamics. A positive cardiotonic response in DCCP patients appeared in 80.2% of those treated. A significant relationship existed between serum concentrations of lanicor and enhancement of myocardial contractility. The therapeutic concentration ranged from 1.2 to 1.9 ng/ml. A mean effective dose equalled 2.0 mg, whereas a recommended average maintenance dose 0.6 mg. The elimination coefficient reached 30%. Resistance to the drug occurred in 19.8% of the patients in the lack of correlation between the therapeutic dose and clinical effect.

• Authors: V A Orlov, L I Zavolovskaia, A G Barkhanova, A M Romanenko
• Journal: Klinicheskaia meditsina (Klin Med (Mosk)) Vol. 68 Issue 10 Pg. 64-5 (Oct 1990) ISSN: 0023-2149 [Print] Russia (Federation)
• Vernacular Title: Effektivnost' lanikora v lechenii bol'nykh khronicheskim legochnym serdtsem.
• PMID: 2077284 (Publication Type: English Abstract, Journal Article)

Chemical References

• Tablets
• Digoxin

Topics

• Adult
• Aged
• Chronic Disease
• Digoxin (adverse effects, pharmacokinetics, therapeutic use)
• Drug Evaluation
• Female
• Hemodynamics (drug effects)
• Humans
• Male
• Middle Aged
• Pulmonary Heart Disease (blood, drug therapy, physiopathology)
• Radioimmunoassay
• Tablets